Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (GB:0QIU)
LSE:0QIU
Holding GB:0QIU?
Track your performance easily
See the Price Targets and Ratings of:
0QIU Analyst Ratings
Moderate Buy
10 Buy
6 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0QIU Stock 12 Month Forecast
Average Price Target
kr814.20
▲(39.72% Upside)
| Highest Price Targetkr1,075 | Average Price Targetkr814.20 | Lowest Price Targetkr515.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Guggenheim
Reiterated
01/17/25
J.P. Morgan
Reiterated
01/17/25
Bank of America Securities
Reiterated
01/17/25
Bernstein
Reiterated
01/15/25
Kepler Capital
Reiterated
01/13/25
Deutsche Bank
Reiterated
01/10/25
Goldman Sachs
Reiterated
01/10/25
Berenberg Bank
Reiterated
01/06/25
Jefferies
Reiterated
01/06/25
DZ BANK AG
―
Hold
―
Reiterated
12/23/24
DZ BANK AG Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Stifel Nicolaus
kr955→kr780
Buy
33.86%
Upside
Reiterated
12/23/24
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK780 at StifelStifel analyst Eric Le Berrigaud lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK780.00 (from DKK955.00) while maintaining a Buy rating.
Handelsbanken Capital
kr1,000
Buy
71.61%
Upside
Upgraded
12/23/24
Novo Nordisk upgraded to Outperform from Market Perform at HandelsbankenNovo Nordisk upgraded to Outperform from Market Perform at Handelsbanken
Barclays
kr1,050→kr900
Buy
54.45%
Upside
Reiterated
12/23/24
Novo Nordisk price target lowered to DKK 900 from DKK 1,050 at BarclaysNovo Nordisk price target lowered to DKK 900 from DKK 1,050 at Barclays
Exane BNP Paribas
kr930
Buy
59.60%
Upside
Upgraded
12/02/24
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP ParibasNovo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
Best Analysts Covering Novo Nordisk
Which Analyst Should I Follow If I Want to Buy GB:0QIU and Sell After:
1 Month
xxx
Success Rate
15/17 ratings generated profit
Average Return
+6.21%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 88.24% of your transactions generating a profit, with an average return of +6.21% per trade.
3 Months
xxx
Success Rate
12/17 ratings generated profit
Average Return
+7.51%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +7.51% per trade.
1 Year
Success Rate
41/53 ratings generated profit
Average Return
+26.26%
reiterated a buy rating 2 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 77.36% of your transactions generating a profit, with an average return of +26.26% per trade.
2 Years
xxx
Success Rate
38/53 ratings generated profit
Average Return
+33.12%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.70% of your transactions generating a profit, with an average return of +33.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0QIU Analyst Recommendation Trends
Rating
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Strong Buy
0
0
0
1
5
Buy
26
23
27
24
25
Hold
12
15
19
20
18
Sell
4
4
3
7
7
Strong Sell
0
0
0
0
0
total
42
42
49
52
55
Each month's total comprises the sum of three months' worth of ratings.
0QIU Financial Forecast
0QIU Stock Forecast FAQ
What is GB:0QIU’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is kr814.20.
What is GB:0QIU’s upside potential, based on the analysts’ average price target?
Novo Nordisk has 39.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novo Nordisk a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 6 hold ratings and 1 sell ratings.
What is Novo Nordisk’s share price target?
The average share price target for Novo Nordisk is kr814.20. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr1,075.00 ,and the lowest forecast is kr515.00. The average share price target represents 39.72% Increase from the current price of kr582.72.
The highest analyst share price target is kr1,075.00 ,and the lowest forecast is kr515.00. The average share price target represents 39.72% Increase from the current price of kr582.72.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Novo Nordisk?
To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.